Active Pharmaceutical Ingredients CDMO Market (API-CDMO) by Drug (Generics, Innovative), Product (Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, Traditional Active Pharmaceutical Ingredient), Synthesis, Workflow, Application

The Active Pharmaceutical Ingredients CDMO Market size was estimated at USD 114.85 billion in 2023, USD 126.42 billion in 2024, and is expected to grow at a CAGR of 10.38% to reach USD 229.39 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Active Pharmaceutical Ingredients CDMO Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Active Pharmaceutical Ingredients CDMO Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients CDMO Market, highlighting leading vendors and their innovative profiles. These include 5N Plus, A. R. Life Sciences Pvt. Ltd., AbbVie Inc., abcr GmbH, Biocon Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Corden Pharma International GmbH, Curia Global, Inc., Dr. Reddy’s Laboratories Ltd., Evonik Industries AG, IOL Chemicals and Pharmaceuticals Limited, Jungbunzlauer Suisse AG, Lonza Group Ltd., Lupin Limited, Minafin Group, Mylan Inc., Olon S.p.A., Piramal Group, PMC Group, Inc., Polpharma SA, Recipharm AB, Samsung Biologics, SEQENS, Siegfried AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, and Xellia Pharmaceuticals ApS by Novo Holdings A/S.

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug
- Generics
- Innovative
Product
- Antibody Drug Conjugate
- Highly Potent Active Pharmaceutical Ingredient
- Traditional Active Pharmaceutical Ingredient
Synthesis
- Biotech
- Synthetic
Workflow
- Clinical
- Commercial
Application
- Cardiovascular
- Diabetes
- Glaucoma
- Hormonal
- Oncology

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Active Pharmaceutical Ingredients CDMO Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Active Pharmaceutical Ingredients CDMO Market?
What are the technology trends and regulatory frameworks in the Active Pharmaceutical Ingredients CDMO Market?
What is the market share of the leading vendors in the Active Pharmaceutical Ingredients CDMO Market?
Which modes and strategic moves are suitable for entering the Active Pharmaceutical Ingredients CDMO Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Active Pharmaceutical Ingredients CDMO Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand for generic drugs and increasing consumption of biopharmaceuticals
5.1.1.2. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
5.1.1.3. Growing demand for targeted cancer and other medical treatments
5.1.2. Restraints
5.1.2.1. Issues associated with compliances while outsourcing
5.1.3. Opportunities
5.1.3.1. Increasing R&D investment for active pharmaceutical ingredients CDMO
5.1.3.2. Proliferating sophistication in oncology drug research
5.1.4. Challenges
5.1.4.1. Stringent regulatory compliance requirements for API CDMO
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Active Pharmaceutical Ingredients CDMO Market, by Drug

6.1. Introduction
6.2. Generics
6.3. Innovative

7. Active Pharmaceutical Ingredients CDMO Market, by Product

7.1. Introduction
7.2. Antibody Drug Conjugate
7.3. Highly Potent Active Pharmaceutical Ingredient
7.4. Traditional Active Pharmaceutical Ingredient

8. Active Pharmaceutical Ingredients CDMO Market, by Synthesis

8.1. Introduction
8.2. Biotech
8.3. Synthetic

9. Active Pharmaceutical Ingredients CDMO Market, by Workflow

9.1. Introduction
9.2. Clinical
9.3. Commercial

10. Active Pharmaceutical Ingredients CDMO Market, by Application

10.1. Introduction
10.2. Cardiovascular
10.3. Diabetes
10.4. Glaucoma
10.5. Hormonal
10.6. Oncology

11. Americas Active Pharmaceutical Ingredients CDMO Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. 5N Plus
15.1.2. A. R. Life Sciences Pvt. Ltd.
15.1.3. AbbVie Inc.
15.1.4. abcr GmbH
15.1.5. Biocon Limited
15.1.6. Boehringer Ingelheim International GmbH
15.1.7. Cambrex Corporation
15.1.8. Catalent, Inc.
15.1.9. Corden Pharma International GmbH
15.1.10. Curia Global, Inc.
15.1.11. Dr. Reddy’s Laboratories Ltd.
15.1.12. Evonik Industries AG
15.1.13. IOL Chemicals and Pharmaceuticals Limited
15.1.14. Jungbunzlauer Suisse AG
15.1.15. Lonza Group Ltd.
15.1.16. Lupin Limited
15.1.17. Minafin Group
15.1.18. Mylan Inc.
15.1.19. Olon S.p.A.
15.1.20. Piramal Group
15.1.21. PMC Group, Inc.
15.1.22. Polpharma SA
15.1.23. Recipharm AB
15.1.24. Samsung Biologics
15.1.25. SEQENS
15.1.26. Siegfried AG
15.1.27. Sun Pharmaceutical Industries Limited
15.1.28. Teva Pharmaceutical Industries Ltd.
15.1.29. Tiefenbacher API + Ingredients GmbH & Co. KG
15.1.30. Xellia Pharmaceuticals ApS by Novo Holdings A/S
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET RESEARCH PROCESS
FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2023 VS 2030
FIGURE 3. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET DYNAMICS
FIGURE 7. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 10. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
FIGURE 12. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
FIGURE 14. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 16. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

5N Plus
A. R. Life Sciences Pvt. Ltd.
AbbVie Inc.
abcr GmbH
Biocon Limited
Boehringer Ingelheim International GmbH
Cambrex Corporation
Catalent, Inc.
Corden Pharma International GmbH
Curia Global, Inc.
Dr. Reddy’s Laboratories Ltd.
Evonik Industries AG
IOL Chemicals and Pharmaceuticals Limited
Jungbunzlauer Suisse AG
Lonza Group Ltd.
Lupin Limited
Minafin Group
Mylan Inc.
Olon S.p.A.
Piramal Group
PMC Group, Inc.
Polpharma SA
Recipharm AB
Samsung Biologics
SEQENS
Siegfried AG
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.
Tiefenbacher API + Ingredients GmbH & Co. KG
Xellia Pharmaceuticals ApS by Novo Holdings A/S

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	198
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 126.42 Billion
Forecasted Market Value ( USD ) by 2030	$ 229.39 Billion
Compound Annual Growth Rate	10.3%
Regions Covered	Global
No. of Companies Mentioned	30

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3372EUR$3,545USD£2,840GBP €3747EUR$3,939USD£3,155GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€4237EUR$4,454USD£3,568GBP €4708EUR$4,949USD£3,964GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5966EUR$6,272USD£5,024GBP €6629EUR$6,969USD£5,583GBP

Active Pharmaceutical Ingredients CDMO Market (API-CDMO) by Drug (Generics, Innovative), Product (Antibody Drug Conjugate, Highly Potent Active Pharmaceutical Ingredient, Traditional Active Pharmaceutical Ingredient), Synthesis, Workflow, Application - Forecast 2024-2030

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Active Pharmaceutical Ingredients CDMO Market by Drug, Product, Synthesis, Workflow, Application - Global Forecast 2025-2030

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

Active Pharmaceutical Ingredient Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Active Pharmaceutical Ingredients CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029